vs

Side-by-side financial comparison of Dorman Products, Inc. (DORM) and Freedom Holding Corp. (FRHC). Click either name above to swap in a different company.

Freedom Holding Corp. is the larger business by last-quarter revenue ($628.6M vs $537.9M, roughly 1.2× Dorman Products, Inc.). Freedom Holding Corp. runs the higher net margin — 12.1% vs 2.1%, a 10.0% gap on every dollar of revenue. On growth, Dorman Products, Inc. posted the faster year-over-year revenue change (0.8% vs -4.1%). Freedom Holding Corp. produced more free cash flow last quarter ($651.7M vs $33.5M). Over the past eight quarters, Freedom Holding Corp.'s revenue compounded faster (16.3% CAGR vs 7.1%).

Dorman Products is an American manufacturer of aftermarket automotive products in the United States. The company was founded in 1918. The company trades on the NASDAQ under the ticker DORM. The company is headquartered in Colmar, Pennsylvania.

Freedom Holding Corp. is an investment conglomerate registered in Nevada, USA. The company provides a range of services in retail financial securities brokerage and trading, asset management, capital markets, investment research and counseling, investment banking and underwriting services, mortgages, insurance, banking and other consumer services. Its main area of focus is in the American stock market, as well as the markets of Europe and Central Asia, mainly Kazakhstan.

DORM vs FRHC — Head-to-Head

Bigger by revenue
FRHC
FRHC
1.2× larger
FRHC
$628.6M
$537.9M
DORM
Growing faster (revenue YoY)
DORM
DORM
+4.8% gap
DORM
0.8%
-4.1%
FRHC
Higher net margin
FRHC
FRHC
10.0% more per $
FRHC
12.1%
2.1%
DORM
More free cash flow
FRHC
FRHC
$618.2M more FCF
FRHC
$651.7M
$33.5M
DORM
Faster 2-yr revenue CAGR
FRHC
FRHC
Annualised
FRHC
16.3%
7.1%
DORM

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
DORM
DORM
FRHC
FRHC
Revenue
$537.9M
$628.6M
Net Profit
$11.6M
$76.2M
Gross Margin
42.6%
96.0%
Operating Margin
5.8%
14.9%
Net Margin
2.1%
12.1%
Revenue YoY
0.8%
-4.1%
Net Profit YoY
-78.8%
-2.6%
EPS (diluted)
$0.38
$1.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DORM
DORM
FRHC
FRHC
Q4 25
$537.9M
$628.6M
Q3 25
$543.7M
$526.1M
Q2 25
$541.0M
$533.4M
Q1 25
$507.7M
$363.7M
Q4 24
$533.8M
$655.2M
Q3 24
$503.8M
$580.9M
Q2 24
$503.0M
$450.7M
Q1 24
$468.7M
$464.7M
Net Profit
DORM
DORM
FRHC
FRHC
Q4 25
$11.6M
$76.2M
Q3 25
$76.4M
$38.7M
Q2 25
$58.7M
$30.4M
Q1 25
$57.5M
$-142.7M
Q4 24
$54.5M
$78.3M
Q3 24
$55.3M
$114.7M
Q2 24
$47.4M
$34.4M
Q1 24
$32.8M
$95.2M
Gross Margin
DORM
DORM
FRHC
FRHC
Q4 25
42.6%
96.0%
Q3 25
44.4%
97.1%
Q2 25
40.6%
97.4%
Q1 25
40.9%
96.6%
Q4 24
41.5%
98.6%
Q3 24
40.5%
99.1%
Q2 24
39.6%
99.0%
Q1 24
38.7%
Operating Margin
DORM
DORM
FRHC
FRHC
Q4 25
5.8%
14.9%
Q3 25
19.4%
11.5%
Q2 25
15.2%
7.6%
Q1 25
15.8%
-42.7%
Q4 24
16.3%
15.0%
Q3 24
15.7%
22.1%
Q2 24
14.4%
9.2%
Q1 24
11.6%
22.5%
Net Margin
DORM
DORM
FRHC
FRHC
Q4 25
2.1%
12.1%
Q3 25
14.1%
7.4%
Q2 25
10.9%
5.7%
Q1 25
11.3%
-39.2%
Q4 24
10.2%
11.9%
Q3 24
11.0%
19.7%
Q2 24
9.4%
7.6%
Q1 24
7.0%
20.5%
EPS (diluted)
DORM
DORM
FRHC
FRHC
Q4 25
$0.38
$1.25
Q3 25
$2.48
$0.63
Q2 25
$1.91
$0.50
Q1 25
$1.87
$-2.35
Q4 24
$1.76
$1.29
Q3 24
$1.80
$1.89
Q2 24
$1.53
$0.57
Q1 24
$1.05
$1.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DORM
DORM
FRHC
FRHC
Cash + ST InvestmentsLiquidity on hand
$49.4M
$869.2M
Total DebtLower is stronger
$440.6M
Stockholders' EquityBook value
$1.5B
$1.4B
Total Assets
$2.5B
$12.4B
Debt / EquityLower = less leverage
0.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DORM
DORM
FRHC
FRHC
Q4 25
$49.4M
$869.2M
Q3 25
$55.5M
$636.0M
Q2 25
$56.8M
$567.9M
Q1 25
$60.6M
$837.3M
Q4 24
$57.1M
$577.9M
Q3 24
$45.1M
$569.2M
Q2 24
$47.5M
$718.7M
Q1 24
$34.4M
$545.1M
Total Debt
DORM
DORM
FRHC
FRHC
Q4 25
$440.6M
Q3 25
Q2 25
Q1 25
Q4 24
$468.8M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
DORM
DORM
FRHC
FRHC
Q4 25
$1.5B
$1.4B
Q3 25
$1.5B
$1.2B
Q2 25
$1.4B
$1.2B
Q1 25
$1.3B
$1.2B
Q4 24
$1.3B
$1.3B
Q3 24
$1.2B
$1.3B
Q2 24
$1.2B
$1.1B
Q1 24
$1.2B
$1.2B
Total Assets
DORM
DORM
FRHC
FRHC
Q4 25
$2.5B
$12.4B
Q3 25
$2.6B
$10.3B
Q2 25
$2.5B
$9.7B
Q1 25
$2.4B
$9.9B
Q4 24
$2.4B
$9.1B
Q3 24
$2.4B
$8.8B
Q2 24
$2.3B
$8.5B
Q1 24
$2.2B
$8.3B
Debt / Equity
DORM
DORM
FRHC
FRHC
Q4 25
0.30×
Q3 25
Q2 25
Q1 25
Q4 24
0.36×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DORM
DORM
FRHC
FRHC
Operating Cash FlowLast quarter
$41.6M
$717.8M
Free Cash FlowOCF − Capex
$33.5M
$651.7M
FCF MarginFCF / Revenue
6.2%
103.7%
Capex IntensityCapex / Revenue
1.5%
10.5%
Cash ConversionOCF / Net Profit
3.60×
9.42×
TTM Free Cash FlowTrailing 4 quarters
$75.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DORM
DORM
FRHC
FRHC
Q4 25
$41.6M
$717.8M
Q3 25
$12.2M
$535.3M
Q2 25
$8.5M
$480.8M
Q1 25
$51.2M
$1.3B
Q4 24
$71.4M
$-72.8M
Q3 24
$44.3M
$-438.0M
Q2 24
$63.3M
$854.1M
Q1 24
$52.0M
$309.0M
Free Cash Flow
DORM
DORM
FRHC
FRHC
Q4 25
$33.5M
$651.7M
Q3 25
$1.8M
$456.4M
Q2 25
$98.0K
$450.0M
Q1 25
$40.3M
Q4 24
$63.2M
$-92.7M
Q3 24
$35.7M
$-447.5M
Q2 24
$51.4M
$829.9M
Q1 24
$41.2M
FCF Margin
DORM
DORM
FRHC
FRHC
Q4 25
6.2%
103.7%
Q3 25
0.3%
86.7%
Q2 25
0.0%
84.4%
Q1 25
7.9%
Q4 24
11.8%
-14.1%
Q3 24
7.1%
-77.0%
Q2 24
10.2%
184.1%
Q1 24
8.8%
Capex Intensity
DORM
DORM
FRHC
FRHC
Q4 25
1.5%
10.5%
Q3 25
1.9%
15.0%
Q2 25
1.6%
5.8%
Q1 25
2.2%
Q4 24
1.5%
3.0%
Q3 24
1.7%
1.6%
Q2 24
2.4%
5.4%
Q1 24
2.3%
Cash Conversion
DORM
DORM
FRHC
FRHC
Q4 25
3.60×
9.42×
Q3 25
0.16×
13.82×
Q2 25
0.15×
15.82×
Q1 25
0.89×
Q4 24
1.31×
-0.93×
Q3 24
0.80×
-3.82×
Q2 24
1.34×
24.83×
Q1 24
1.58×
3.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DORM
DORM

Light Duty$428.6M80%
Heavy Duty$55.8M10%
Specialty Vehicle$53.5M10%

FRHC
FRHC

Segment breakdown not available.

Related Comparisons